Diary

  • Mon
    09
    Apr
    2018

    Royal Marsden Hospital

    Description: In this course I describe the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. I also explain the scientific rationale behind targeted treatments in use and in development for these diseases, such as EGFR inhibitors, ALK and ROS1 inhibitors, B-Raf inhibitors, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.
    Level: Intermediate/Advanced
    Audience: Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
    Cost: TBC
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

  • Wed
    09
    May
    2018

    Royal Marsden Hospital, London

    Description: In this course I describe the faulty genes, pathways and proteins that drive colorectal, head and neck, pancreatic, oesophageal, gastric and primary liver cancer. I also explain the science behind many targeted treatment approaches for these diseases, including EGFR- and HER2-targeted antibodies, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.
    Level: Intermediate/Advanced
    Audience: Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
    Cost: TBC
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

  • Mon
    11
    Jun
    2018

    Half dayRoyal Marsden Hospital, London

    Description: A half-day course repeated morning and afternoon describing the theory behind the new immunotherapy treatments for cancer such as checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab), adoptive cell transfer (CAR T cell therapy, infiltrating T cells), and vaccine-based treatments (peptide and DNA vaccines, oncolytic viruses, dendritic cell vaccines).
    Level: Intermediate
    Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

  • Tue
    26
    Jun
    2018

    Royal Marsden Hospital

    Description: Using a combination of colourful diagrams and clear explanations, I will describe the gene mutations and other defects that drive ovarian cancer (including fallopian tube and other primary peritoneal cancers). I will also examine how this knowledge impacts treatment choice and explain the science behind chemotherapy and PARP, B-Raf and angiogenesis inhibitors. The day will also include the potential of immunotherapy and novel approaches for treatment, screening and patient monitoring.
    Level: Intermediate
    Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
    Cost: TBC
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

     

  • Wed
    11
    Jul
    2018

    Royal Marsden Hospital, London

    Description: In this study day I describe the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments for leukaemias, lymphomas and multiple myeloma. Treatments explained include a wide range of monoclonal antibodies, B cell receptor signalling blockers and JAK2, Bcl-2, FLT3 and CDK inhibitors. I also explore the potential of immunotherapy with checkpoint inhibitors and CAR T cells.
    Level: Intermediate/Advanced
    Audience:Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
    Cost: TBC
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

  • Thu
    13
    Sep
    2018

    All dayManchester Airport

    This study day is being organised by Amgen.
    Elaine will deliver the morning session, covering:

    Part 1:
    The cellular and genetic make-up of acute lymphoblastic leukaemia (ALL)
    • A bit about B cells
    • Genetic drivers of ALL
    • Clonal evolution & intratumoural heterogeneity
    • The role of leukaemic stem cells

    Treating Philadelphia Chromosome Positive ALL
    • Bcr-Abl inhibitors
    • Other treatments

    Part 2:
    Licensed and novel treatments for ALL
    • Blinatumumab
    • Inotuzumab ozogamicin
    • CAR-modified T cells
    • Other treatments in trials

    Contact Elaine if you would like to know how to book a place.

    View the programme

  • Sun
    14
    Oct
    2018

    9:15 - 10:15Birmingham

    Elaine will be delivering a plenary session on Sunday morning.

    View the full programme:

    http://www.bopawebsite.org/sites/default/files/imce/BOPA1803-Agenda-2018.pdf

  • Tue
    04
    Dec
    2018

    Royal Marsden Hospital, London

    Description: 1-day course covering a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. Treatments described include: growth factor receptor inhibitors, kinase inhibitors, monoclonal antibodies, PARP inhibitors, ALK inhibitors, CDK inhibitors, immunotherapies.
    Level: Advanced
    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses
    Cost:
    £150
    To book, contact: conferenceteam@rmh.nhs.uk
    View an outline of the programme